Centrosomal PKCβII and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Angiogenesis is critical in the progression of prostate cancer. However, the interplay between the proliferation kinetics of tumor endothelial cells (angiogenesis) and tumor cells has not been investigated. Also, protein kinase C (PKC) regulates various aspects of tumor cell growth, but its role in prostate cancer has not been investigated in detail. Here, we found that the proliferation rates of endothelial and tumor cells oscillate asynchronously during the growth of human prostate cancer xenografts. Furthermore, our analyses suggest that PKCβII was activated during increased angiogenesis and that PKCβII plays a key role in the proliferation of endothelial cells and tumor cells in human prostate cancer; treatment with a PKCβII-selective inhibitor, βIIV5-3, reduced angiogenesis and tumor cell proliferation. We also find a unique effect of PKCβII inhibition on normalizing pericentrin (a protein regulating cytokinesis), especially in endothelial cells as well as in tumor cells. PKCβII inhibition reduced the level and mislocalization of pericentrin and normalized microtubule organization in the tumor endothelial cells. Although pericentrin has been known to be up-regulated in epithelial cells of prostate cancers, its level in tumor endothelium has not been studied in detail. We found that pericentrin is up-regulated in human tumor endothelium compared with endothelium adjacent to normal glands in tissues from prostate cancer patients. Our results suggest that a PKCβII inhibitor such as βIIV5-3 may be used to reduce prostate cancer growth by targeting both angiogenesis and tumor cell growth. [Cancer Res 2008;68(16):6831–9]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
Cited by
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Self-citationProtein kinase C: poised to signal
Newton, A. C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2009 · Cited by 512
Protein kinase C and cancer: what we know and what we do not
Garg, R., Benedetti, L. G., Abera, M. B., Wang, H., Abba, M., & Kazanietz, M. G. (2014) · Oncogene · doi:10.1038/onc.2013.524 · Cited by 303
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
Cell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 256
Metadata
- Authors
- Kim, J., Choi, Y.-L., Vallentin, A., Hunrichs, B. S., Hellerstein, M. K., Peehl, D. M., & Mochly-Rosen, D.
- Venue
- Cancer Research
- Published
- 2008-08-12
- Volume
- 68
- Issue
- 16
- Pages
- 6831-6839
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2172263810
- Cited by
- 54
- References
- 1
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Centrosomal PKCβII and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-6195
- The paper
- Kim, J., Choi, Y.-L., Vallentin, A., Hunrichs, B. S., Hellerstein, M. K., Peehl, D. M., & Mochly-Rosen, D. (2008). Centrosomal PKCβII and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-6195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.